Low (0-5) Alberta Stroke Program Early Computed Tomography Score on Admission Predictive of Worse Functional Outcome after Mechanical Thrombectomy for Anterior Circulation Large Vessel Occlusion

DOI: https://doi.org/10.21203/rs.3.rs-2067919/v1

Abstract

BACKGROUND AND PURPOSE

We examined functional outcomes of mechanical thrombectomy (MT) procedures following anterior circulation large vessel occlusion (ACLVO)-related acute ischemic strokes (AIS). Results were based on admission non-contrast computed tomography (NCCT) studies, using the Alberta Stroke Program Early Computed Tomography Score (ASPECTS) as standard metric.

METHODS

Qualifying subjects were consecutive patients (N = 327) at a single center undergoing MT for ACLVO-related AIS. Each was grouped according to ASPECTS status on admission, determined from NCCT images by two physicians. Primary clinical endpoint was functional independence, assessed via modified Rankin Scale (mRS) at 90 days. Secondary endpoints were vessel recanalization (ie, modified Thrombolysis in Cerebral Infarction [mTICI] score), symptomatic intracranial hemorrhage (sICH), and mortality.

RESULTS

In this study population (mean age, 63.6 ± 12.5 years; women, 29.3%; median baseline National Institute of Health Stroke Scale [NIHSS] score, 15.2 ± 4.5), patients were stratified by ASPECTS tier at presentation, either 0–5 (n = 43) or 6–10 (n = 284). Multivariate logistic regression showed a relation between ASPECTS values ≤ 5 and lesser chance of 90-day functional improvement (OR = 1.40, 95% confidence interval [CI]: 1.00-5.80; p = 0.049), once adjusted for age, baseline NIHSS score, diabetes mellitus, atrial fibrillation/flutter, current/prior alcohol intake, HbA1c concentration, D-dimer level, occlusion of internal carotid artery (ICA), occlusion of ICA and middle cerebral artery (ICA + MCA), numbers of device passes, and successful recanalization.

CONCLUSIONS

ASPECTS values ≤ 5 correspond with worse long-term functional improvement (mRS scores > 2) in patients undergoing MT for ACLVO-related AIS. Other independent determinants of functional outcomes after MT are age, baseline NIHSS score, HbA1c concentration, and successful recanalization.

Introduction

Domestic and foreign studies have validated the Alberta Stroke Program Early Computed Tomography Score (ASPECTS) as a standardized quantitative metric, reflecting the extent of infarction in instances of acute anterior circulation large vessel occlusion (ACLVO) [1, 2]. Recent reports have also demonstrated that this simple and reliable measure may serve to identify the most suitable patients for endovascular therapy and function as a prognostic index [3]. According to American Heart Association/American Stroke Association guidelines, the standard of care in adult patients with ASPECTS values ≥ 6 and large-vessel occlusion is endovascular therapy [4, 5]. However, much of the research on mechanical thrombectomy (MT) has excluded patients with lower ASPECTS values (≤ 6 or 7), failing to fully address the prognostic utility of ASPECTS in MT-treated patients [6, 7].

In the present study, we compared ASPECTS values of NCCT studies on admission with clinical consequences of MT (including successful recanalization, functional improvement, symptomatic intracranial hemorrhage [sICH], and mortality), hoping to facilitate the planning of MT procedures.

Methods

Patient selection

This was a single-center retrospective observational analysis of 327 consecutive patients with ACLVO-related AIS treated by MT between January 2016 and August 2022. The hospital's institutional review board approved our study protocol.

Eligible MT-treated subjects met the following inclusion criteria: (1) adult ≥18 years; (2) availability of non-contrast computed tomography (NCCT) imaging done on admission; and (3) proximal anterior circulation occlusion involving internal carotid artery (ICA) or M1/proximal M2 branch of middle cerebral artery (MCA), as shown by computed tomography angiography (CTA) or digital subtraction angiography (DSA). The following were grounds for study exclusion: (1) prior severe stroke, with baseline National Institutes of Health Stroke Scale (NIHSS) score≤8 or baseline modified Rankin Scale (mRS) score≥1; (2) farction on baseline CT; or (3) other brain abnormalities, such as tumors or trauma (shown in Fig. 1).

 Data collection

We retrieved baseline patient characteristics (age and sex), medical history (including prior stroke, coronary artery disease, atrial fibrillation/flutter, hypertension, hyperlipidemia, or diabetes mellitus), and lifestyle habits (current/prior tobacco use, alcohol intake), as well as clinical parameters on admission (ie, NIHSS score, diastolic [DBP] and systolic [SBP] blood pressure readings, glycosylated hemoglobin [HbA1c] concentration, D-dimer level, and presence of hyperdense middle cerebral artery sign [HMCAS] or signs of early infarction on NCCT) and intravenous injection of tissue plasminogen activator (tPA) from electronic medical records. Other clinical variables, including trial of ORG 10172 in acute stroke treatment (TOAST) classification, occlusive location, stroke-onset to puncture time, number of device passes, and use of balloon-guided catheter or angioplasty/stenting, were also recorded.

All NCCT studies were performed by Discovery CT 750 HD scanner (GE Healthcare, Chicago, IL, USA) at the following settings: tube voltage, 100 kV; tube current, 120 mA; collimator width, 40mm; field of view, 25cm; layer thickness, 5mm; layer spacing, 5mm. Two neuroradiologists blinded to clinical outcomes separately determined ASPECTS values for each patient. Inconsistencies were resolved by imaging reviews, reaching consensus decisions through discussion.

In ASPECTS determinations, MCA vascular supply has 10 defined territories [1], including seven regions of caudate nucleus and layers below (M1, M2, M3, insula [I], lenticular nucleus[L], caudate nucleus [C], and posterior limb of internal capsule [IC]) and three areas of cerebral cortex above the nucleus(M4, M5, and M6). Maximum score is 10 points, subtracting 1 point for each injured area (shown in Fig. 2).

Clinical outcomes

The primary study endpoint was long-term functional independence, measured by mRS at 90 days. Secondary endpoints were successful vascular reperfusion immediately following MT (ie, modified Thrombolysis in Cerebral Infarction [mTICI] score of 2b or 3); symptomatic intracranial hemorrhage (sICH), indicated by≥4-point decline in NIHSS score or CT evidence of hemorrhage within 24 hours post-MT; and mortality.

 Statistical analysis

All computations were driven by standard software (SPSS v22.6; IBM Corp, Armonk, NY, USA). Categorical variables were expressed as frequencies and percentages. The Shapiro-Wilk test was applied to determine normality of distributions. Continuous variables with non-normal distributions were expressed as mean ± standard deviation (SD) or median (interquartile range [IQR]) values. Normally distributed continuous variables were subjected to Student’s t-test, assesssing non-normal variables by Mann-Whitney test and categorical variables by Fisher’s exact or χ2 test. Multivariate logistic regression analysis served to identify independent predictors of clinical outcomes. Results were presented as odds ratios (ORs) with 95% confidence intervals (CIs), setting significance at p<0.05. 

Results

Baseline patient characteristics

The 327 qualifying patients were grouped according to ASPECTS tier (0–5, 43; 6–10, 284). Mean age was 63.6 ± 12.5 years, and 96 (29.3%) were women. A summary of group parameters is provided in Table 1. Members of the low-scoring (0–5) group exhibited more extreme presentations than did high-scoring (6–10) group members (mean baseline NIHSS score: 18.1 ± 5.2 vs 14.7 ± 4.2; p < 0.001). Likewise, HMCAS positivity (76.7% vs 60.2%; p = 0.037) and signs of early infarction (93.0% vs 59.2%; p < 0.001) were significantly more prevalent in the low-scoring (vs high-scoring) group.

  Clinical outcomes

Clinical outcomes are shown by group in Table 2. Unlike the high (6-10) ASPECTS tier, low-tier (0-5) members were less inclined to show good clinical outcomes (mRS scores 0-2) at 90 days (32.6% vs 49.3%; p=0.041) (shown in Fig. 3), demonstrating higher rates of sICH (39.5% vs 21.8%; p=0.012) and mortality (18.6% vs 8.8%; p=0.047). However, successful reperfusion rates did not differ significantly in the two groups (76.7% vs 74.6%; p=0.0768).

 Predictors of worse functional outcomes (mRS scores >2)

Table 3 contains a listing of unfavorable prognosticators, including older age (p<0.001), higher baseline NIHSS score (p<0.001), histories of diabetes mellitus (p<0.001) or atrial fibrillation/flutter (p=0.014), current/prior alcohol intake(p=0.034), increased HbA1c concentration (p<0.001), elevated D-dimer level (p<0.001), occlusion of ICA (p=0.003), non-occlusion of ICA+MCA (p=0.024), number of device passes(p=0.024), successful reperfusion (p<0.001), and initial ASPECTS value ≤5 (p=0.043).

In multivariate logistic regression, a relation between ASPECTS of ≤ 5 and worse functional outcome (mRS score >2) at 90 days (OR=1.40, 95% CI: 1.00-5.80; p=0.049) emerged, once adjusted for age, NIHSS score, diabetes mellitus, atrial fibrillation/flutter, current/prior alcohol intake, HbA1c concentration, D-dimer level, occlusion of ICA, occlusion of ICA+MCA, number of device passes, and successful reperfusion (Table4).

Discussion

The Discussion/Conclusion should provide an evaluation of the results. There should be a clear discussion of the implications, significance, and novelty of the results presented and whether the data support or contradict previous studies.

Present findings indicate that ASPECTS values ≤ 5 on admission NCCT studies reduce the likelihood of long-term functional independence and increase the odds of sICH and mortality after MT in patients with ACLVO-related AIS. On the other hand, higher ASPECTS values (6–10) herald significantly better clinical outcomes and carry less risk of death. These associations proved significant in multivariate regression analysis, with other independent predictors emerging as well.

ASPECTS is a simple and convenient, topographic method of semiquantitatively gauging early ischemic core infarct volume and is deemed strongly predictive of clinical outcomes in the setting of AIS [1]. Typically, it is a stipulation for enrollment in various randomized intravascular treatment trials. Because past efforts seemed to restrict the merits of MT to patients with ASPECTS values ≥ 6, subsequent clinical trials have tended to exclude those with lesser scores [68]. Indeed, a recent meta-analysis of such studies undertaken by Phan et al to explore ASPECTS as a basis for revascularization suitability has demonstrated the prognostic favorability of a higher (vs lower) ASPECTS status in the course of endovascular thrombectomy [8]. However, more and more efforts are showing that patients with lower ASPECTS values may well benefit from MT under certain conditions [912]. In a subgroup analysis of the MR CLEAN randomized phase 3 trial, patients with ASPECTS values of 5–7 were regarded as acceptable candidates for endovascular therapy, otherwise weighing potential treatment benefit and cost-effectiveness of endovascular therapy (in conjunction with various influential factors) at values of 0–4 [3]. An analysis from the STRATIS Registry, conducted by Zaidat et al and aimed at impacts of age and low (0–5) ASPECTS status (ie, large infarcts) on MT outcomes, has also revealed better clinical outcomes and lower risk of death inpatients < 65 (vs > 75) years of age[11].

When comparing our two ASPECTS tiers (0–5 vs 6–10), there was no significant difference in rates of successful recanalization (mTICI scores > 2b). Yet, 90-day functional outcomes in low-scoring patients were better if vessel recanalization was achieved. In MT-treated patients with low ASPECTS values (0–5), Kaesmacher et al have similarly linked successful recanalization to better outcomes and safety profiles [10]. Results of a meta-analysis by Cagnazzo et al also suggest that patients with ASPECTS values of 0–6 may benefit from MT, with successful recanalization not only heightening the probability of long-term functional improvement but also reducing sICH occurrences. Still, only about one of four patients with ASPECTS values of 4 retained functional independence after MT, and just 14% had favorable functional outcomes at ASPECTS values of 0–3 [9].

Above findings are compatible with ours, rates of functional independence, sICH, and mortality for the two ASPECTS tiers (0–5 vs 6–10) being significantly different. ASPECTS determinations ≤ 5 also strongly signaled worse 90-day clinical outcomes in our multivariable logistic regression model (Table 4).Ultimately, ASPECTS status is a measure of infarct size, an apparent correlate of functional outcomes after endovascular reperfusion therapy [13, 14]. At lower scores, patients simply have less salvageable volumes of brain tissue and larger infarct volumes, both for shadowing functional deficits.

Until now, identifying patients who might benefit most from endovascular therapy after strokes has remained a serious question. According to our data, younger age, lower baseline NIHSS score, lower HbA1c concentration, and successful recanalization are all independent predictors of favorable outcomes after MT, regardless of ASPECTS status. These parameters are also aligned with reported findings in a series of endovascular therapy recipients [11, 1519].

For a variety of reasons, we did not examine diffusion-weighted imaging (DWI) or computed tomography angiography (CTA) studies in this cohort. NCCT remains the most accessible and economical diagnostic tool for emergency use in patients with strokes, and it is often all that time allows. Moreover, symptom severity or existing contraindications may prohibit DWI or CTA scanning procedures.

There are several limitations of this study worth mentioning. First, this was a single-center endeavor, with a relatively sparse sampling of low-scoring patients (ASPECTS 0–5) that may have skewed the results. In addition, all ASPECTS determinations were based entirely on NCCT images; and given the scarcity of patients with the lowest of scores (ASPECTS 0–3), comparative analysis within the lower ASPECTS tier (4–5 vs 0–3) was not feasible. Whether the lowest-scoring patients (0–3) actually benefit from MT remains a topic for further study. The findings provided herein must be corroborated as well by multicenter prospective studies that entail other methods of examination.

Conclusion

ASPECTS values ≤ 5 signal worse long-term functional status (mRS scores > 2) in patients with ACLVO-related AIS undergoing MT. Older age, elevated HbA1c concentration, and higher baseline NIHSS score are other independent risk factors for poor clinical outcomes, whereas successful recanalization is protective of functional independence.

Abbreviations

MT

mechanical thrombectomy

AIS

acute ischemic strokes

ACLVO

anterior circulation large vessel occlusion

NCCT

non-contrast computed tomography

ASPECTS

Alberta Stroke Program Early Computed Tomography Score

mRS

modified Rankin Scale

sICH

symptomatic intracranial hemorrhage

mTICI

modified Thrombolysis in Cerebral Infarction

NIHSS

National Institute of Health Stroke Scale

ICA

internal carotid artery

MCA

middle cerebral artery

CTA

computed tomography angiography

DSA

digital subtraction angiography

DBP

diastolic blood pressure

SBP

systolic blood pressure

HMCAS

hyperdense middle cerebral artery sign

tPA

tissue plasminogen activator

TOAST

trial of ORG 10172 in acute stroke treatment



Declaration

Statement of Ethics

The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The Local Ethics Committee [the Institutional Review Board of the General Hospital of the Northern Theater Command] approved the study protocol and provided the reference number (Approval Number Y (2020) 012).

Because the study was retrospective, the General Hospital of the Northern Theater Command Institutional Review Board does not require written informed consent.

Consent for publication

Not Applicable.

Data Availability Statement

The datasets generated and/or analysed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.

Conflict of Interest Statement

The authors have no conflicts of interest to declare. 

Funding Sources

This work was supported by Project of Natural Science Foundation of Shenyang (grant no.20-205-4-044), Project of Natural Science Foundation of Liaoning Province (grant no.201602768) and Key Research and the Development Program of Liaoning Province, China (grant no.2020JH2/10300119).

Author Contributions

JL and YD: the conception and design of the study. JL and JD: acquisition of data. JC, JL and LZ: analysis and interpretation of data. JL and YD: drafting the article or revising it critically for important intellectual content. YD and BY: final approval of the version to be submitted.

Acknowledgement 

We thank Qiuxiao Li for help in collecting clinical data.

References

  1. Barber, P.A., et al., Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. The Lancet, 2000. 355(9216): p. 1670-1674.
  2. Arne Potreck , A.F., Fatih Seker, Charlotte S Weyland, Sibu Mundiyanapurath, Sabine Heiland, Martin Bendszus and Johannes AR Pfaff, Accuracy and reliability of PBV ASPECTS, CBV ASPECTS and NCCT ASPECTS in acute ischaemic stroke a matched-pair analysis. The neuroradiology journal, 2021. 0(0): p. 1-8.
  3. Yoo, A.J., et al., Effect of baseline Alberta Stroke Program Early CT Score on safety and efficacy of intra-arterial treatment: a subgroup analysis of a randomised phase 3 trial (MR CLEAN). The Lancet Neurology, 2016. 15(7): p. 685-694.
  4. Powers, W.J., et al., 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2018. 49(3): p. e46-e110.
  5. Eskey, C.J., et al., Indications for the Performance of Intracranial Endovascular Neurointerventional Procedures: A Scientific Statement From the American Heart Association. Circulation, 2018. 137(21): p. e661-e689.
  6. Berkhemer, O.A., et al., A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med, 2015. 372(1): p. 11-20.
  7. Albers, G.W., et al., Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med, 2018. 378(8): p. 708-718.
  8. Phan, K., et al., Influence of ASPECTS and endovascular thrombectomy in acute ischemic stroke: a meta-analysis. Journal of NeuroInterventional Surgery, 2019. 11(7): p. 664-669.
  9. Cagnazzo, F., et al., Mechanical thrombectomy in patients with acute ischemic stroke and ASPECTS </=6: a meta-analysis. J Neurointerv Surg, 2020. 12(4): p. 350-355.
  10. Kaesmacher, J., et al., Mechanical Thrombectomy in Ischemic Stroke Patients With Alberta Stroke Program Early Computed Tomography Score 0-5. Stroke, 2019. 50(4): p. 880-888.
  11. Zaidat, O.O., et al., Impact of Age and Alberta Stroke Program Early Computed Tomography Score 0 to 5 on Mechanical Thrombectomy Outcomes: Analysis From the STRATIS Registry. Stroke, 2021. 52(7): p. 2220-2228.
  12. Goyal, N., et al., A multicenter study of the safety and effectiveness of mechanical thrombectomy for patients with acute ischemic stroke not meeting top-tier evidence criteria. J Neurointerv Surg, 2018. 10(1): p. 10-16.
  13. Yoo, A.J., et al., MRI-based selection for intra-arterial stroke therapy: value of pretreatment diffusion-weighted imaging lesion volume in selecting patients with acute stroke who will benefit from early recanalization. Stroke, 2009. 40(6): p. 2046-54.
  14. Olivot, J.M., et al., Impact of diffusion-weighted imaging lesion volume on the success of endovascular reperfusion therapy. Stroke, 2013. 44(8): p. 2205-11.
  15. Goyal, N., et al., Admission hyperglycemia and outcomes in large vessel occlusion strokes treated with mechanical thrombectomy. J Neurointerv Surg, 2018. 10(2): p. 112-117.
  16. Tonetti, D.A., et al., Successful reperfusion, rather than number of passes, predicts clinical outcome after mechanical thrombectomy. J Neurointerv Surg, 2020. 12(6): p. 548-551.
  17. Diprose, W.K., et al., Glycated hemoglobin (HbA1c) and outcome following endovascular thrombectomy for ischemic stroke. J Neurointerv Surg, 2020. 12(1): p. 30-32.
  18. Khan, M.A., et al., Endovascular treatment of acute ischemic stroke in nonagenarians compared with younger patients in a multicenter cohort. J Neurointerv Surg, 2017. 9(8): p. 727-731.
  19. Nogueira, R.G., et al., Predictors of good clinical outcomes, mortality, and successful revascularization in patients with acute ischemic stroke undergoing thrombectomy: pooled analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI Trials. Stroke, 2009. 40(12): p. 3777-83.

Tables

Table 1.Baseline patient characteristics, overall and by ASPECTS determinations

Characteristic

Overall
 (N=327)

ASPECTS0-5  (n=43)

ASPECTS 6-10  (n=284)

P-value

Age, y

63.6±12.5

60.4±10.8

64.1±12.7

0.026

Female

96 (29.3)

7 (16.3)

89 (31.3)

0.044

Hypertension

189 (57.6)

26 (60.5)

163 (57.4)

0.704

Diabetes mellitus

89 (27.1)

10 (23.3)

79 (27.8)

0.532

Hyperlipidemia

100 (30.5)

18 (41.9)

82 (28.9)

0.085

Atrial fibrillation/flutter

125 (38.1)

18 (41.9)

107 (37.7)

0.599

Coronary artery disease

64 (19.5)

7 (16.3)

57 (20.1)

0.560

Current/prior tobacco use

164 (50.0)

24 (55.8)

140 (49.3)

0426

Current/prior alcohol intake

158 (48.2)

24 (55.8)

134 (47.2)

0.292

TOAST classification

8 (2.4)

 

 

0.242

Large artery atherosclerosis

248 (75.6)

36 (83.7)

212 (74.6)

 

Cardioembolism

71 (21.6)

5 (11.6)

66 (23.2)

 

Other determined etiology

8 (2.4)

2 (4.7)

6 (2.1)

 

Prestroke

67 (20.4)

6 (14.0)

61 (21.5)

0.255

Baseline NIHSS

15.2±4.5

18.1±5.2

14.7±4.2

<0.001

HMCAS

204 (62.2)

33 (76.7)

171 (60.2)

0.037

Signs of early infarction

208 (63.4)

40 (93.0)

168 (59.2)

<0.001

DBP on admission, mmHg 

141.1±25.2

135.8±27.7

141.8±24.6

0.070

SBP on admission, mmHg 

83.0±15.1

82.9±14.7

83.1±15.3

0.879

HbA1c, mmol/L 

7.5±3.4

8.8±5.8

7.2±2.8

0.189

D-dimer, mmol/L

2.6±4.1

2.8±3.1

2.6±4.3

0.066

Occlusive location

 

 

 

0.273

ICA

85 (25.9)

14 (32.6)

71 (25.0)

 

MCA M1

142 (43.3)

18 (41.9)

124 (43.7)

 

MCA M2

21 (6.4)

0 (0.0)

21 (7.4)

 

ICA+MCA

79 (24.1)

11 (25.6)

68 (23.9)

 

IV tPA

81 (24.7)

7 (16.3)

74 (26.1)

0.167

Oneset to puncture, min

499.5±392.3

468.4±244.5

504.3±410.3

0.627

Device passes

1.7±0.9

1.8±0.9

1.6±0.8

0.198

Balloon-guided catheter

78 (23.8)

9 (20.9)

69 (24.3)

0.630

Angioplasty and stenting

24 (7.3)

3 (7.0)

21 (7.4)

0.922

Significant values in bold

Data expressed as n (%) or mean ± standard devation values

*ASPECTS, Alberta Stroke Program Early CT Score; TOAST, Trial of Org 10172 in Acute Stroke Treatment; NIHSS, National Institutes of Health Stroke Scale; HMCAS, hyperdense middle cerebral artery sign; DBP, diastolic blood pressure; SBP, systolic blood pressure; HbA1c, glycosylated hemoglobin; ICA, internal carotid artery; MCA, middle cerebral artery; IV tPA, intravenous tissue plasminogen activator

 Table 2.Clinical outcomes of patients, overall and by ASPECTS determinations

Outcomes

Overall

(N=327)

ASPECTS0-5(n=43)

ASPECTS6-10(n=284)

P-value

mTICI score

 

 

 

 

0

25 (7.6)

7 (16.3)

18 (6.3)

0.001

1

24 (7.3)

2 (4.7)

22 (7.7)

0.469

2a

33 (10.1)

1 (2.3)

32 (11.3)

0.070

2b

106 (32.3)

31 (72.1)

75 (26.4)

0.001

3

139 (42.4)

2 (4.7)

137 (48.2)

0.001

Successful reperfusion 

245 (74.7)

33 (76.7)

212 (74.6)

0.768

Symptomatic ICH 

79 (24.1)

17 (39.5)

62 (21.8)

0.012

Good functional outcomes (mRS score<2) at 90 days

154 (47.0)

14 (32.6)

140 (49.3)

0.041

90-day mRS score

3.0±1.3

3.5±1.5

2.9±1.3

0.043

Mortality

33 (10.1)

8 (18.6)

25 (8.8)

0.047

Significant values in bold

Data expressed as n (%) or mean±standard devation values

*ASPECTS, Alberta Stroke Program Early CT Score; mTICI, modified Thrombolysis in Cerebral Infarction; mRS, modified Rankin Scale; ICH, intracranial hemorrhage

 Table 3.Predictors of functional outcome at 90 days (univariate ordinal regression)

Characteristic

OR

95%CI

P-value

Age, y

1.07

1.05-1.09

<0.001

Female

1.45

0.90-2.35

0.132

Hypertension

1.22

0.79-1.90

0.369

Diabetes mellitus

2.45

1.47-4.10

<0.001

Hyperlipidemia

0.80

0.50-1.28

0.348

Atrial fibrillation/flutter

1.77

1.13-2.79

0.014

Coronary artery disease

1.63

0.93-2.85

0.088

Current/prior tobacco use

0.68

0.44-1.06

0.086

Current/prior alcohol intake

0.62

0.40-0.97

0.034

TOAST classification

0.82

0.53-1.27

0.368

Large artery atherosclerosis

 

 

 

Cardioembolism

 

 

 

Other determined etiology

 

 

 

Prestroke

1.53

088-2.65

0.129

Baseline NIHSS score

1.14

1.07-1.20

<0.001

HMCAS

0.90

0.58-1.42

0.060

Signs of early infarction

1.53

0.97-2.40

0.068

DBP on admission

1.00

0.99-1.00

0.310

SBP on admission

1.00

0.97-1.00

0.091

HbA1c

1.51

1.29-1.77

<0.001

D-dimer

1.15

1.04-1.27

0.006

Occlusive location

 

 

 

ICA

2.21

1.32-3.71

0.003

MCA M1

0.81

0.53-1.26

0.357

MCA M2

1.20

0.49-2.93

0.688

ICA+MCA

0.55

0.33-0.92

0.024

IV tPA

1.01

0.61-1.67

0.970

Oneset to puncture, min

0.99

0.99-1.00

0.056

Device passes

1.47

1.13-1.93

0.005

Balloon-guided catheter

0.75

0.45-1.25

0.268

Angioplasty and stenting

1.86

0.77-4.48

0.166

Successful reperfusion

0.34

0.20-0.58

<0.001

Symptomatic ICH

1.63

0.97-2.74

0.063

ASPECTS≤5

2.01

1.02-3.97

0.043

Significant values in bold

*TOAST, Trial of Org 10172 in Acute Stroke Treatment; NIHSS, National Institutes of Health Stroke Scale; HMCAS, hyperdense middle cerebral artery sign; DBP, diastolic blood pressure; SBP, systolic blood pressure; HbA1c, glycosylated hemoglobin; ICA, internal carotid artery; MCA, middle cerebral artery; IV tPA, intravenous tissue plasminogen activator; ASPECTS, Alberta Stroke Program Early CT Score

 Table 4.Multivariate logistic regression model of functional independence (mRS score 0-2 at 90d)

Predictor

Odds ratio

95%CI

P-value

ASPECTS≤5

1.40

1.00-5.80

0.049

Age 

1.09

1.06-1.12

<0.001

HbA1c

1.43

1.17-1.73

<0.001

Baseline NIHSS 

1.12

1.04-1.21

0.002

Successful reperfusion

0.32

0.15-0.66

0.002

Significant values in bold

*ASPECTS, Alberta Stroke Program Early CT Score; HbA1c, glycosylated hemoglobin; NIHSS, National Institutes of Health Stroke Scale